|
| 36920087 | Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. | Diabetes Care | 2023 |
| 37918404 | Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes. | Cell Rep Med | 2023 |
| 37758901 | Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes. | Commun Biol | 2023 |
| 37667106 | High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. | Diabetologia | 2023 |
| 37794253 | Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. | Nat Med | 2023 |
| 37502867 | Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. | medRxiv | 2023 |
| 37432736 | Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes. | JCI Insight | 2023 |
| 34593707 | Single Nucleotide Variant in FAS Associates With Organ Failure and Soluble Fas Cell Surface Death Receptor in Critical Illness. | Crit Care Med | 2022 |
| 35608267 | Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. | Am J Physiol Lung Cell Mol Physiol | 2022 |
| 35980300 | Clinical and experimental treatment of type 1 diabetes. | Clin Exp Immunol | 2022 |
| 35025103 | Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes. | Eur J Immunol | 2022 |
| 35020411 | Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. | Sci Transl Med | 2022 |
| 33351781 | Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. | JCI Insight | 2021 |
| 33483981 | The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes. | Immunol Cell Biol | 2021 |
| 33662335 | Combination therapy in recent-onset type 1 diabetes. | Lancet Diabetes Endocrinol | 2021 |
| 33658358 | Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. | Sci Transl Med | 2021 |
| 35072168 | A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. | Immunother Adv | 2021 |
| 34747368 | IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. | JCI Insight | 2021 |
| 34214479 | Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Diabetes Endocrinol | 2021 |
| 33125521 | Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice. | Diabetologia | 2021 |
| 33097590 | A distinct GM-CSF<sup>+</sup> T helper cell subset requires T-bet to adopt a T<sub>H</sub>1 phenotype and promote neuroinflammation. | Sci Immunol | 2020 |
| 31815738 | Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. | J Clin Invest | 2020 |
| 30830871 | B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. | JCI Insight | 2019 |
| 31671072 | A composite immune signature parallels disease progression across T1D subjects. | JCI Insight | 2019 |
| 31722988 | Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells. | J Immunol | 2019 |
| 31221801 | Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances. | Diabetes | 2019 |
| 31157632 | Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. | Curr Opin Endocrinol Diabetes Obes | 2019 |
| 30894366 | Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. | Diabetes | 2019 |
| 29769438 | Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome. | JCI Insight | 2018 |
| 29842945 | Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. | Clin Immunol | 2018 |
| 29473705 | Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics. | Pediatr Diabetes | 2018 |
| 28844471 | Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. | Cell Immunol | 2017 |
| 28645874 | Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. | Clin Immunol | 2017 |
| 27629486 | Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. | Sci Transl Med | 2016 |
| 28664195 | Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. | Sci Immunol | 2016 |
| 25634360 | Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. | J Autoimmun | 2015 |
| 26249556 | Association of common polymorphisms in the IL2RA gene with type 1 diabetes: evidence of 32,646 individuals from 10 independent studies. | J Cell Mol Med | 2015 |
| 26448755 | Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways. | Int J Cell Biol | 2015 |
| 26606968 | Type 1 diabetes immunotherapy using polyclonal regulatory T cells. | Sci Transl Med | 2015 |
| 26193635 | Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. | J Clin Invest | 2015 |
| 24576418 | Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance. | Clin Immunol | 2014 |
| 23363979 | In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. | Sci Transl Med | 2013 |
| 24376757 | Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. | PLoS One | 2013 |
| 23600824 | Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes. | Clin Exp Immunol | 2013 |
| 23807601 | Intersection between genetic polymorphisms and immune deviation in type 1 diabetes. | Curr Opin Endocrinol Diabetes Obes | 2013 |
| 23499139 | IL-2 therapy in type 1 diabetes: "Trials" and tribulations. | Clin Immunol | 2013 |
| 22721971 | Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. | Diabetes | 2012 |
| 21179116 | An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. | Genes Immun | 2011 |
| 21865550 | Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. | J Immunol | 2011 |
| 21856944 | CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. | J Immunol | 2011 |